Vincenzo Salamone

Urology resident, Careggi Hospital, University of Florence, Italy. _______________________________________ *I don't like to blow my own trumpet*

[Matt Cooperberg @dr_coops]

Dear everyone presenting slides that were obviously AI generated & you clearly didn’t even bother to edit:

Please stop.

Thank you.

Sincerely,
Every audience

[Toni Choueiri, MD @DrChoueiri]

My picks in #GU Oncology for #ESMO2026. Exciting new data to be presented @myESMO !

[Yüksel Ürün @DrYukselUrun]

Listen to your patient; he is telling you the diagnosis.
- Sir William Osler

[Musab Ali Kutluhan @DrMusab]

It has been a true privilege to complete my observership at the Department of Urology, Careggi Hospital, Florence. I would like to express my sincere gratitude to Prof. Andrea Minervini and his team for their kindness, support, and willingness to share their expertise. Having the opportunity to closely follow wide variety of robotic urologic cases of Prof. Minervini, one of the world’s leading robotic urologic surgeon, was an unforgettable experience that will have a lasting impact on my robotic surgical practice and academic career. Grazie @minerviniandre @andreamari08 @GrossoAnton

[Enrique Grande @drenriquegrande]

⚡️KEYNOTE-B15/EV-304 published in @NEJM: perioperative EV + pembrolizumab vs cisplatin-gemcitabine in cisplatin-eligible MIBC.

Significant improvements in EFS, OS and pCR. The perioperative standard now extends to all MIBC patients candidates for cystectomy.

https://t.co/vLWW1n3pqg

#BladderCancer

[NEJM @NEJM]

Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) https://t.co/y4G27hfORg

Editorial: Breaking the RAS Barrier in Pancreatic Cancer https://t.co/DbeFbZsu9r

#Oncology

[Enrique Grande @drenriquegrande]

KEYNOTE-905/EV-303 in @NEJM: perioperative enfortumab vedotin + pembrolizumab vs surgery alone in cisplatin-ineligible MIBC (n=344).

pCR: 57.1% vs 8.6%
2-year EFS: 74.7% vs 39.4% (HR 0.40)
2-year OS: 79.7% vs 63.1% (HR 0.50)

The perioperative standard in cisplatin-ineligible MIBC.

https://t.co/3FsYt402uh

#BladderCancer #MIBC #GUOncology

[Prof. Feynman @ProfFeynman]

The more you teach, the better you learn.
Teaching is a powerful tool for learning.

[Tom Powles @tompowles1]

The FDA approval of perioperative EVP in muscle invasive bladder cancer makes platinum eligable somewhat redundant. It creates a paradigm shift in the disease and a is landmark moment . The principle of ‘EVP first, ask questions later’ becomes more relevant. The next questions are i) can we cure most of these patients without surgery and ii) how much systemic therapy is needed? @Annals_Oncology @OncoAlert

[Società Italiana di Urologia @SIU_Italia]

Nel trial STITCH, la chiusura fasciale con passaggi <1 cm (“small bites”) ha ridotto le ernie incisionali dal 49% al 34% e dimezzato le ernie clinicamente significative dopo 13 anni di follow-up.

https://t.co/5Giorjzwxn

[Fernando GomezSancha @fgomsan]

ThuLEP series (n=629, WJU 2026): men with preop urge incontinence recover urgency on a slower clock. Persistent UUI at 3 mo: 64% vs 29%; by 12mo, it converges (7.4% vs 2.7%). Voiding improves first; storage relief takes more time. https://t.co/H4oDm9bIuP

[Challenges in Laparoscopy & Robotics ( CILR ) @CILR2027]

📍Rome, June 3rd, 2026: we kick off!
The Congress opens with one of the leading figures in robotic surgery: @minerviniandre , 2025 Course Director, performing a remarkable multiport RAPN live.
Innovation, vision, and surgical excellence—setting the stage for three unmissable days

[Tom Powles @tompowles1]

Nectin-4 is expressed in almost all urothelial cancers . Nectin-4 fluorescence imaging during cystoscopy makes sense and seems to work well (see below) #EAU26 @urotoday . This potentially improves diagnostic accuracy. It would be good to generate large randomized data. @OncoAlert

[Tom Powles @tompowles1]

The final analysis (9 year follow up) of checkmate 214 (IPI/Nivo vs sunitinib - 1st line RCC) @Annals_Oncology. Durable remissions with 31% 9 yr OS. Long-term benefit for IMDC good risk despite lower initial response rates (HR 0.80). OS HR for int/poor at 0.68. It remains a standard of care, and the best 1st line option for some (including good risk). @DrChoueiri @OncoAlert

[NEJM @NEJM]

In high-risk biochemically recurrent prostate cancer, enzalutamide plus leuprolide significantly improved overall survival as compared with leuprolide alone. Enzalutamide monotherapy had no significant benefit for survival. Full phase 3 EMBARK trial results and Research Summary: https://t.co/jwAROfr840

[Andrea Minervini @minerviniandre]

@RicBertolo @EurUrolOncol @bernardorocco73 @PaoloVerze @antopastl @lucacindolo @foxal72 @EAU_Uroonco @aleantonellibs1 @AgileGroupUro Discussing RT toxicity is not an attack on anyone, but responsibility for urologist that treat them. Late complic are real and often end up with cistectomy that often it is not the end of pts suffering. Scientific debate should be grounded in clinical reality, not in its denial.

[Alessandro Antonelli MD FRCS(Glasg) @aleantonellibs1]

This study should be approached with respect: it's a prospective case series peer-reviewed and published in a leading journal after rigorous evaluation; objective real-world data on late GU toxicity often emerge years after RT therefore frequently managed outside RT oncology.

[Toni Choueiri, MD @DrChoueiri]

IT IS THIS TIME OF THE YEAR AGAIN!

TOP 10 GU clinical trials in 2025!

1/ Practice-changing IMvigor011: In ctDNA+ MIBC post-cystectomy, adjuvant atezo improved DFS (HR 0.64) & OS (HR 0.59) vs placebo. ctDNA- pts spared therapy w/ 2-yr DFS ~88%.
@tompowles1 @DrYukselUrun @OncoBellmunt @NEJM #ESMO2025 Plenary @myESMO

https://t.co/mbl2VKLZ2N

[Tom Powles @tompowles1]

Perioperative Enfortumab Vedotin and pembrolizumab beats neoadjuvant chemotherapy & cystectomy in muscle invasive bladder cancer. We’re moving towards a bladder surgery sparing strategies using EVP. This is another step towards curing bladder cancer https://t.co/UEV0JiM1iC

[JAMA @JAMA_current]

✅ Editor’s Choice: This Review summarizes the epidemiology, clinical presentation, pathophysiology, and management of renal cell #carcinoma (RCC). In 2023, there were an estimated 81 800 newly diagnosed cases of RCC in the US.

💾 Save this Review for your citations: https://t.co/UaTEDlDtZg